AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate

Published:2017-01 Issue:1 Volume:197 Page:135-142
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Todenhöfer Tilman¹²,Azad Arun³⁴,Stewart Craig¹,Gao Jian¹,Eigl Bernhard J.³,Gleave Martin E.¹,Joshua Anthony M.⁵,Black Peter C.¹,Chi Kim N.¹³

Affiliation:

1. Vancouver Prostate Centre, University of British Columbia, British Columbia, Vancouver, Canada

2. Department of Urology, University Hospital, Tübingen, Germany

3. British Columbia Cancer Agency, British Columbia, Vancouver, Canada

4. Department of Medicine, Monash University, Melbourne, Victoria, Australia

5. Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference30 articles.

1. Enzalutamide in metastatic prostate cancer before chemotherapy;Beer;N Engl J Med,2014

2. Increased survival with enzalutamide in prostate cancer after chemotherapy;Scher;N Engl J Med,2012

3. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial;Fizazi;Lancet Oncol,2014

4. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial

5. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study;Ryan;Lancet Oncol,2015

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Castration-resistant prostate cancer monitoring by cell-free circulating biomarkers;Frontiers in Oncology;2024-09-10

2. The positive relationship between androgen receptor splice variant-7 expression and the risk of castration-resistant prostate cancer: A cumulative analysis;Frontiers in Oncology;2023-02-14

3. AR and PI3K/AKT in Prostate Cancer: A Tale of Two Interconnected Pathways;International Journal of Molecular Sciences;2023-01-20

4. Efficacy of cabazitaxel and androgen splicing variant-7 status in circulating tumor cells in Asian patients with metastatic castration-resistant prostate cancer;Scientific Reports;2022-10-26

5. Liquid biopsy‐based targeted gene screening highlights tumor cell subtypes in patients with advanced prostate cancer;Clinical and Translational Science;2022-09-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3